A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up As a Booster Dose During a New Pregnancy
Latest Information Update: 19 Jun 2025
At a glance
- Drugs GBS NN (Primary)
- Indications Streptococcal infections
- Focus Pharmacodynamics
- Sponsors Minervax
Most Recent Events
- 13 Mar 2025 Planned End Date changed from 30 Jun 2030 to 30 Jun 2029.
- 13 Mar 2025 Planned primary completion date changed from 30 Jun 2030 to 30 Jun 2029.
- 13 Mar 2025 Status changed from not yet recruiting to recruiting.